4: Central Nervous System

Size: px
Start display at page:

Download "4: Central Nervous System"

Transcription

1 Original Date of issue: 26/11/2005 Last eviewed:10/10/2012 Version:4 Page 1 of 25 4: entral Nervous System 4.1 Hypnotics and anxiolytics Hypnotics Temazepam SF Solution (10mg/5ml) Temazepam Tablets (10mg) Zolpidem Tablets (5mg) Zopiclone Tablets (3.75mg, 7.5mg) omments SM advice: 1. Benzodioazepines are indicated for the short term relief (two to four weeks only) of anxiety that is severe, disabling or subjecting the individual to unacceptable distress occurring alone or in association with insomnia or short term psychosomatic, organic or psychotic illness. 2. The use of benzodiazepines to treat short term mild anxiety is inappropriate and unsuitable 3. Benzodiazepines should be used to treat insomnia only when it is severe, disabling or subjecting the individual to extreme distress Non benzodiazepine hypnotics that act at the benzodiazepine receptor. Licensed for short term treatment of insomnia Formulary Nitrazepam Suspension (2.5mg/5ml) Nitrazepam Tablets (5mg) hloral Hydrate Solution (500mg/5ml) Anxiolytics estricted to existing patients who come into hospital on it. See SM advise above For inpatient use only. Any outpatient prescriptions or discharges should be checked with the paediatric pharmacist and discussions should include whether chrloal hydrate mg/5ml (Welldorm) could be used instead as this is much more economical in the community.

2 Original Date of issue: 26/11/2005 Last eviewed:10/10/2012 Version:4 Page 2 of 25 hlordiazepoxide apsules (5mg, 10mg Diazepam Solution (2mg/5ml, 5mg/5ml) Diazepam Tablets (2mg, 5mg, 10mg) Lorazepam Injection (4mg/1ml) Lorazepam Tablets (1mg, 2.5mg) Oxazepam Tablets (10mg, 15mg) Formulary Buspirone 5mg Tablets onsultant Psychiatrist use only for short term treatment of anxiety 4.2 Drugs used in psychoses and related disorders Antipsychotic drugs hlorpromazine Syrup (25mg/5ml) hlorpromazine Injection (50mg/2ml) hlorpromazine Tablets (10mg, 25mg, 50mg, 100mg) hlorpromazine Suppositories (100mg) hlorpromazine Suspension (100mg/5ml) Flupentixol Tablets (3mg) Fluphenazine Tablets (1mg, 2.5mg) Haloperidol Injection (5mg/1ml) Haloperidol apsules (500micrograms) Haloperidol Tablets (1.5mg, 5mg) Haloperidol SF Solution (5mg/5ml) Levomepromazine Tablets (25mg) Promazine Tablets (25mg) Promazine Syrup (25mg/5ml) Sulpiride SF Solution (200mg/5ml) Sulpiride Tablets (200mg, 400mg) Trifluoperazine M capsules (2mg, 10mg,15mg) Trifluoperazine Tablets (1mg, 5mg) Trifluoperazine Syrup (1mg/5ml) Trifluoperazine Solution (5mg/5ml) Zuclopenthixol Tablets (2mg, 10mg, 25mg) Zuclopenthixol Injection (50mg/1ml, 100mg/2ml) Formulary

3 Original Date of issue: 26/11/2005 Last eviewed:10/10/2012 Version:4 Page 3 of 25 Benperidol Tablets (250micrograms) Benperidol is used in treatment of deviant antisocial behavious but its value is not established. To be prescribed by onsultant Psychiatrists only Pimozide Tablets (4mg) eserved for existing patients only

4 Original Date of issue: 26/11/2005 Last eviewed:10/10/2012 Version:4 Page 4 of 25 Atypical antipsychotics Formulary Amisulpride Tablets (50mg, For onsultant Psychiatrist use only 200mg, 100mg) Amisulpride 500mg/5ml Solution For onsultant Psychiatrist use only Aripiprazole Tablets (5mg, For onsultant Psychiatrist use only. 10mg, 15mg, 30mg) lozapine Tablets (25mg, 100mg) lozapine Liquid (100mg/5ml) For onsultant Psychiatrist use only. egistration needed for all patients on this drug. Levomepromazine Tablets (25mg) Levomepromazine Injection (25mg/ml) Olanzapine Tablets (2.5mg, 5mg, 7.5mg, 10mg, 15mg) Olanzapine Orodispersible Tablets (5mg, 10mg, 15mg, 20mg) For onsultant Psychiatrist use and for palliative care For onsultant Psychiatrist use only For onsultant Psychiatrist use only For use only in patients with swallowing difficulites Olanzapine Injection (10mg) For onsultant Psychiatrist use only Quetiapine Starter Pack Quetiapine Tablets (25mg, 50mg, 100mg, 150mg, 200mg, 300mg) Quetiapine M Tablets (200mg, 300mg) For onsultant Psychiatrist use only Quetiapine M tablets are much more expensive than the immediate release tablets isperidone Liquid (5mg/5ml) For onsultant Psychiatrist use only isperidone Tablets (500micrograms, 1mg, 2mg, 3mg) For onsultant Psychiatrist use only isperidone Orodispersible Tablets (500micrograms, 1mg, 2mg, 3mg) isperidone Injection (25mg, 37.5mg, 50mg) Antipsychotic depot injections For onsultant Psychiatrist use only For use only in patients with swallowing difficulites For onsultant Psychiatrist use only Flupentixol Decanoate Injection (20mg/1ml, 40mg/2ml, 50mg/0.5ml, 100mg/1ml, 200mg/1ml)

5 Original Date of issue: 26/11/2005 Last eviewed:10/10/2012 Version:4 Page 5 of 25 Fluphenazine Decanoate Injection (100mg /1ml, 50mg/2ml, 25mg/ml, 50mg/0.5ml, 12.5mg/0.5ml) Haloperidol Decanoate Injection (100mg/1ml, 50mg/1ml) Pipotiazine Injection (50mg/1ml, 100mg/2ml) Zuclopenthixol Injection (200mg/1ml, 500mg/1ml) Antimanic drugs First line Others Lithium arbonate M/ Tablets (200mg, 400mg) PIADEL Lithium itrate syrup 509mg (5.4mmol) in 5ml PIADEL Lithium arbonate M/ Tablets (250mg,400mg) AMOLIT omments Lithium carbonate 200mg = lithium citrate 509mg eserved for patients who come in on it Formulary Valproic acid as Semi Sodium Valproate Tablets (250mg, 500mg) Depakote For onsultant Psychiatrist use only for the treatment of manic episodes associated with bipolar depression Should be prescribed by brand 4.3 Antidepressant drugs Tricyclic and related antidepressant drugs Tricyclic and related antidepressants should be used with caution in patients with cardiovascular disease because of the risk of arrhythmias, patient with concomitant condtions such as hyperthyroidism and phaeochromocytoma should be treated witrh care. are is also needed in patient with epilepsy and diabetes. lomipramine apsules (10mg, 25mg, 50mg) lomipramine M Tablets (75mg) lomipramine Injection (25mg/2ml) Dosulepin apsules (25mg) Doxepin apsules (25mg, 50mg) Imipramine Tablets (10mg, 25mg) Lofepramine Tablets (70mg) Lofepramine SF Suspension (70mg/5ml) Nortriptyline Tablets (10mg, 25mg)

6 Original Date of issue: 26/11/2005 Last eviewed:10/10/2012 Version:4 Page 6 of 25 Trazodone Tablets (150mg) Trazodone apsules (50mg, 100mg) Trazodone SF Liquid (50mg/5ml) Trimipramine Tablets (10mg, 25mg)

7 Original Date of issue: 26/11/2005 Last eviewed:10/10/2012 Version:4 Page 7 of 25 Formulary Amitriptyline SF Solution (25mg/5ml) Amitriptyline Tablets (10mg, 25mg, 50mg) Dosulepin Oral Solution (25mg/5ml, 75mg/5ml) Dosulepin Tablets (75mg) Mianserin Tablets (10mg, 20mg, 30mg) eserved for patient who are admitted on them. Amitriptyline is not routinely recommended as as antidepressant but may be considered for neuropathic pain eserved for patient who are admitted on them eserved for existing patients only Monoamine-oxidase inhibitors Moclobemide Tablets (150mg, 300mg) Phenelzine Tablets (15mg) Selective serotonin re-uptake inhibitors First line italopram Oral Drops (40mg/1ml) italopram Tablets (10mg, 20mg, 40mg) omments 4 oral drops (8mg) is equivalent to a 10mg tablet Please express the dose on the oral drops as drops rather than milligrams. MHA advice italopram and escitalopram are associated with dose dependent QT interval prolongation and should not be used in those with: congenital long QT syndrome; known pre-existing QT interval prolongation; or in combination with other medicines that prolong the QT interval. EG measurements should be considered for patients with cardiac disease, and electrolyte disturbances should be corrected before treatment. For citalopram, new restrictions on the maximum daily dose apply: 40mg for adults; 20mg for patoient over 65years;

8 Original Date of issue: 26/11/2005 Last eviewed:10/10/2012 Version:4 Page 8 of 25 and 20mg for those with hepatic impairment. Fluoxetine apsules (20mg) Fluoxetine Liquid (20mg/5ml) Second line Paroxetine Tablets (10mg, 20mg, 30mg) Paroxetine SF Liquid (10mg/5ml) Sertraline Tablets (50mg, 100mg) Formulary Escitalopram Tablets (10mg, 20mg) onsultant Psychiatrist use only Escitalopram Oral Solution (10mg/ml) MHA advice italopram and escitalopram are associated with dose dependent QT interval prolongation and should not be used in those with: congenital long QT syndrome; known pre-existing QT interval prolongation; or in combination with other medicines that prolong the QT interval. EG measurements should be considered for patients with cardiac disease, and electrolyte disturbances should be corrected before treatment. For escitalopram, the maximum daily dose for patients older than 65 years in now reduced to 10mg/day; other doses remain unchanged Other antidepressant drugs Flupentixol Tablets (500micrograms, 1mg) Formulary Duloxetine apsules (30mg, 60mg) onsultant Psychiatrist use only ymbalta brand only Mirtazapine Orodispersible Tablets onsultant Psychiatrist use only (15mg, 30mg, 45mg) eboxetine Tablets (4mg) onsultant Psychiatrist use only Venlafaxine Tablets (37.5mg, 75mg) onsultant Psychiatrist use only

9 Original Date of issue: 26/11/2005 Last eviewed:10/10/2012 Version:4 Page 9 of 25 Venlafaxine M/ apsules (75mg, 150mg) onsultant Psychiatrist use only For use in patients who have already been stabilised on venlafaxine immediate release tablets 4.4 NS stimulants and other drugs used for attention deficit hyperactivity disorder affeine itrate Solution (50mg/5ml) Formulary Methylphenidate Tablets 10mg Methylphenidate Tablets M 20mg onsultant Psychiatrist and Paediatrician use only Modafinil Tablets (100mg) estricted to espiratory onsultant use only for the treatment of excessive daytime sleepiness associated with narcolepsy 4.5 Drugs used in the treatment of obesity NIL Anti-obesity drugs acting on the gastrointestinal tract Formulary Orlistat apsules (120mg) Available for patients who come in on it who are being treated according to NIE G entrally acting appetite suppressants

10 Original Date of issue: 26/11/2005 Last eviewed:10/10/2012 Version:4 Page 10 of Drugs used in nausea and vertigo Link to: Nausea and Vomiting (Postoperative) Management Guideline First line Dexamethasone tabolets 8mg omments Second line Third line Ondansetron tablets (4mg) Ondansetron injection (4mg in 2ml) Ondansetron syrup (4mg in 5ml) Prochlorperazine Injection (12.5mg/1ml) Prochlorperazine Tablets (5mg) Prochlorperazine Buccal Tablets 3mg Prochlorperazine Syrup (5mg/5ml) yclizine Tablets (50mg) yclizine Injection (50mg/ml) yclizine Liquid (25mg/5ml) Metoclopramide Syrup (5mg/5ml) Metoclopramide Injection (10mg/2ml) Metoclopramide Tablets (10mg) Domperidone SF Suspension (5mg/5ml) Domperidone Suppositories (30mg) Domperidone Tablets (10mg) Droperidol injection 2.5mg/ml For use within its licensed indication in accordance with protocol. yclizine is an antihistamine. Dose should be reduced in elderly as it can cause drowsiness Least effective antiemetic but it can relieve full feeling in stomach Extra pyramidal side effects e.g. tremor/dystonia and abnormal eye movements can be reversed with 5-10 mg procyclidine given IM or IV (2.5mg-5mg in elderly) May be administered rectally. Less likely to give rise to sedation and abnormal facial and eye movements onsultant Anaesthetist use only for the prevention and treatment of PONV in adult patients in whom other IV antiemetics are ineffective or contraindicated.

11 Original Date of issue: 26/11/2005 Last eviewed:10/10/2012 Version:4 Page 11 of 25 Formulary Aprepitant 3 day pack apsules (80mg+125mg) Ondansetron Tablet (8mg) Ondansetron Injection (8mg/4ml) Dexamethasone sodium phosphate injection 8mg in 2ml Dexamethasone tablets 2mg Levomepromazine Injection Use supported for during 2 nd and subsequent cycles of cisplatin-based chemotherapy for patients who have had intractable N&V during 1 st cycle despite having 5HT3 antagonist. Prescribed by onsultant Haematologist and Oncologist for prevention of nausea and vomiting induced by highly emetogenic chemotherapy For palliative care use only 25mg/ml Levomepromazine Tablets 25mg For palliative care use and for onsultant Psychiatrist use only Motion sickness Betahistine Tablets (8mg) innarizine Tabets (15mg) Hyoscine hydrobromide (Kwells Tablets) Promethazine theoclate Tablets (25mg) Formulary Hyoscine hydrobromide Patch (1.5mg) (1mg in 72hrs) Hyoscine hydrobromide injection 400micrograms / ml Glycopyrronium bromide tablets (1mg ) eserved for prevention of excessive salivation and reduction of secretions See BNF For use by ommunity Paediatricians. eserved for prevention of excessive salivation and reduction of secretions in patients who cannot tolerate or who do not respond to hyoscine patches. Unlicensed product paperwork required

12 Original Date of issue: 26/11/2005 Last eviewed:10/10/2012 Version:4 Page 12 of Analgesics (Needs to link to pain ladder) Link to Musculoskeletal section for NSAID s Non-opioid analgesics First line Paracetamol aplets (500mg) Paracetamol Tablets (500mg) Paracetamol Suspension (120mg/5ml, 250mg/5ml) Paracetamol Suppositories (60mg, 120mg, 240mg, 500mg) Paracetamol Tablet Soluble (500mg) omments Link to analgesic table Formulary Paracetamol Infusion (1g/100ml) eserved for use in adults, adolescents and children weighing more than 33kg: 1. who have undergone bowel surgery 2. with moderate pain who are unable to take oral analgesia, who already have an IV running and where rectal paracetamol is inappropriate. Paracetamol Infusion (500mg/50ml) eserved for use in term newborn infants, infants, toddlers and children weighing less than 33kg: 1. who have undergone bowel surgery 2. with moderate pain who are unable to take oral analgesia, who already have an IV running and where rectal paracetamol is inappropriate. Nefopam Tablets (30mg) For psychiatric wards only Aspirin Tablets Dispersible (300mg) Aspirin Tablets E (300mg) Aspirin Suppositories (150mg, 300mg)

13 Original Date of issue: 26/11/2005 Last eviewed:10/10/2012 Version:4 Page 13 of Opioid analgesics ompound analgesics ompound analgesic preparations containing paracetamol with a low does of opioid analgesic are commonly used but their advantages have not been substantiated. The low dose of opioid may be enough to cause opioid side effectcs (particularly constipation) and can complicate the treatment of overdoasge yet may not provide significant additional relief of pain. First line o-dydramol 10/500 Tablets (paracetamol 500mg with dihydrocodeine 10mg) o-codamol 8/500 Tablets (paracetamol 500mg, codeine phosphate 8mg) o-codamol 8/500 Effervescent Tablets (paracetamol 500mg, codeine phosphate 8mg) Stronger opioids o-codamol Tablets 30/500 (paracetamol 500mg, codeine phosphate 30mg) odeine Phosphate Tablets (15mg, 30mg, 60mg) odeine Phosphate Injection (60mg/ml) odeine Phosphate Syrup (25mg/5ml) Dihydrocodeine Solution (10mg/5ml) Dihydrocodeine Tablets (30mg) Dihydrocodeine Injection (50mg/1ml) Morphine Sulphate M Tablets (5mg, 10mg, 15mg, 30mg, 60mg, 100mg, 200mg) Morphine Sulphate oral Solution (10mg/5ml, 100mg/5ml) Morphine Sulphate Injection (10mg/1ml, 1mg/ml) Morphine Sulphate Intrathecal Injection (2mg/2ml) Morphine Syringes 50mg/50ml Morphine Injection (50mg/50ml) Morphine Sulphate M Sachets (20mg, 30mg) Tramadol apsules 50mg omments Please use the analgesic ladder as a guide to the treatment of pain. Try to avoid the use of these products as they are not included on the analgesic ladder. Link to analgesic ladder Please ensure that the brand of sustained release morphine is stated on the discharge letter to GP s

14 Original Date of issue: 26/11/2005 Last eviewed:10/10/2012 Version:4 Page 14 of 25 Buprenorphine patches 5mcg/hr BuTrans 10mcg/hr BuTrans 20mcg/hr BuTrans 35mcg/hr Transtec 52.5mcg/hr Transtec 70mcg/hr - Transtec Not to be used in opioid naïve patients. For elderly patients requiring chronic pain relief who are unable to take oral opioid medication or who are non-compliant with syringe drivers. For selected oncology patients. For the BuTrans products, the release is over a 7 day period. For the Transtec products, the release is over a 4 day period. Formulary Alfentanil Injection 1mg/2ml For theatre and IU use only. Alfentanil Injection 5mg/10ml Alfentanil Nasal Spray For Palliative are onsultant s use only 5mg/5ml Alfentanil Injection 5mg/1ml For Palliative are onsultant s use only and IU Buprenorphine Sublingual Tablets (200micrograms, 400micrograms, 2mg, 8mg) Buprenorphine Injection (300mcg/ml) S Diamorphine Injection 5mg Use restricted to: A&E (intranasal use only in children), Labour ward (obstetric use), Theatre & ecovery - For IT/ IV/ epidural use, mainly for obstetric cases, Palliative care (only for patient who have come in and are established on diamorphine - used routinely at Harden ward BH (North Yorkshire PT) for S Diamorphine Injection (10mg, 30mg, 100mg, 500mg) palliative care syringes, initiated by GPs) For aseptic use only for preparation of diamorphine syringes

15 Original Date of issue: 26/11/2005 Last eviewed:10/10/2012 Version:4 Page 15 of 25 Formulary S Dihydrocodeine M/ Tablets (60mg, 90mg, 120mg) Fentanyl Patches (12micrograms, 25micrograms, 50micrograms, 75micrograms, 100micrograms) Fentanyl (Abstral) Sublingual Tablets (S/L) (100mcg, 200mcg, 300mcg, 400mcg) Hydromorphone apsules (1.3mg, 2.6mg) Hydromorphone M/ apsules (2mg, 4mg, 8mg, 16mg, 24mg) Hydromorphone Injection (10mg/1ml, 50mg/1ml) Morphine Sulphate Injection (15mg/1ml,30mg/1ml, 60mg/10ml) Oxycodone Hydrochloride Injection (20mg/2ml, 10mg/1ml) Oxycodone capsules (5mg, 10mg, 20mg) Oxycodone m/r tablets (5mg, 10mg, 20mg, 40mg, 80mg) Oxcodone Liquid (50mg/5ml) Oxcodone SF Liquid (5mg/5ml) Pethidine Injection (100mg/2ml, 50mg/1ml) Papaveretum Injection 15.4mg/ml Papaveretum Injection 7.7mg/ml For use in chronic pain states only Palliative care use or under recommendation by the pain team Please ensure that the brand prescribed is written on the dischsarge prescription Not to be used in opioid naïve patients. For the treatment of breakthrough cancer pain in patients in whom standard treatments (morphine or oxycodone) are ineffective or not tolerated Under Palliative are onsultant s recommendations for patients intolerant of morphine Under Palliative are onsultant s recommendations for patients intolerant of morphine Under Palliative are onsultant s recommendations for patients intolerant of morphine Aseptics use only For Palliative are use only or For use by Palliative are onsultants Second-line after morphine for patients developing intolerable side effects with morphine eserved for obstetric use only Unsuitable for women of childbearing age Syrup BP (66.7%) 50ml For neonatal use only

16 Original Date of issue: 26/11/2005 Last eviewed:10/10/2012 Version:4 Page 16 of 25 Formulary Tramadol M Tablets (100mg) Tramadol Soluble Tablets (50mg) Tramadol M apsules (50mg) Tramadol Injection (100mg/2ml) Tramadol can be used as an alternative to dihydrocodeine or codeine in patient with uncontrolled acute or chronic pain or where side effects of codeine/dihydrocodeine are a problem. The sustained release preparations should not be used for acute pain.

17 Original Date of issue: 26/11/2005 Last eviewed:10/10/2012 Version:4 Page 17 of Neuropathic and functional pain efer to BNF for products. NIE linical Guideline G96 Neuropathic pain pharmacological management Gabapentin apsules (100mg, 300mg, 400mg) Formulary Pregabalin apsules (25mg, 50mg, 75mg, 100mg, 150mg, 200mg, 300mg) For use by Diabetic team for the treatment of diabetic neuropathy (as an alternative to gabapentin and following a trial of a tricyclic drug). For the treatment of neuropathic back pain in patients in whom gabapentin and tricyclics have been ineffective or not tolerated Antimigraine drugs Treatment of the acute migraine attack Treatment of a migraine attack should be guided by response to previous treatment and the severity of the attacks. A simple analgesic such as aspirin, paracetamol (preferably in a soluble or dispersible form) or an NSAID is often effective; concomitant antiemetic treatment may be required. If treatment with an analgesic is inadequate, an attack may be treated with a specific antimigraine compound such as a 5HT 1 agonist (triptan) Analgesics Aspirin see Section Paracetamol see Section Non Steroidal Antiinflammatory Drugs see Section HT 1 agonists Sumatriptan Tablets (50mg, 100mg) Sumatriptan Nasal Spray (10mg/0.1ml, 20mg/0.1ml) Sumatriptan Syringe plus autoinjectors (6mg/0.5ml) Sumatriptan Syringe efill (6mg/0.5ml)

18 Original Date of issue: 26/11/2005 Last eviewed:10/10/2012 Version:4 Page 18 of Prophylaxis of migraine Pizotifen Tablets (500micrograms, 1.5mg) Pizotifen Elixir (250micrograms/5ml) See BNF for other treatments 4.8 Antiepileptics ontrol of epilepsy Antiepileptics should be prescribed by brand arbamazepine SF Liquid (100mg/5ml) arbamazepine chewable Tablets (100mg, 200mg) arbamazepine Tablets (100mg, 200mg) arbamazepine M Tablets (200mg, 400mg) arbamazepine Suppositories (125mg, 250mg) lobazam Tablets (10mg) lonazepam SF Solution (500micrograms/5ml) lonazepam Tablets (500micrograms, 2mg) lonazepam injection 1mg/1ml Ethosuximide apsules (250mg) Ethosuximide Syrup (250mg/5ml) Lamotrigine Tablets (25mg, 50mg, 100mg, 250mg) Lamotrigine Dispersible Tablets (5mg, 25mg, 100mg) Lamotrigine (Lamictal) ewable/ Dispersible Tablets (2mg) Levetiracetam Tablets (250mg, 500mg, 1000mg) Levetiracetam Oral Solution (100mg/ml) Levetiracetam Infusion (100mg/ml) Phenobarbital Tablets (15mg, 30mg, 60mg) Phenobarbital Injection (60mg/1ml, 200mg/ml) Phenobarbital Mixture (15mg/5ml, 50mg/5ml) Phenytoin Injection (250mg/5ml) Phenytoin Suspension (30mg in 5ml) Phenytoin Sodium Injection (250mg/5ml) Phenytoin Sodium apsules (25mg, 50mg, 100mg) Phenytoin Sodium Tablets (50mg, 100mg) Primidone Tablets (250mg) Sodium Valproate (Epilim) SF Liquid (200mg/5ml) Sodium Valproate (Orlept) SF Liquid (200mg/5ml) Sodium Valproate (Epilim) Injection (400mg) Sodium Valproate (Episenta) Injection (300mg/3ml)

19 Original Date of issue: 26/11/2005 Last eviewed:10/10/2012 Version:4 Page 19 of 25 Sodium Valproate (Epilim) E Tablets (200mg, 500mg) Sodium Valproate (Orlept) E Tablets (500mg) Sodium Valproate (Epilim hrono) M Tablets (200mg, 300mg, 500mg) Sodium Valproate (Episenta) M apsules (150mg, 300mg) Sodium Valproate (Episenta) M Sachets (1g, 500mg) Sodium Valproate (Epilim) rushabletablets (100mg) Sodium Valproate (Epilim) Syrup (200mg/5ml) Vigabatrin Tablets (500mg) Vigabatrin Sachets (500mg) Formulary S Topiramate Tablets (25mg, 50mg, 100mg, 200mg) Topiramate Sprinkle aspules (15mg, 25mg) Gabapentin apsules (100mg, 300mg, 400mg) onsultant Neurologist use only Specailist departmental use only Drugs used in epilepticus lonazepam Injection (1mg/1ml) Diazepam Emulsion Injection (10mg/2ml) Diazepam Injection (10mg/2ml) Diazepam ectal Tubes (2.5mg, 5mg, 10mg) Lorazepam Injection (4mg/1ml) Paraldehyde Injection (5ml) Paraldehyde/ Olive Oil Enema 50% (10ml) Formulary Buccolam Midazolam Oromucosal Solution 5mg/ml: 0.5ml (2.5mg) prefilled syringes 1ml (5mg) prefilled syringes 1.5ml (7.5mg) prefilled syringes 2ml (10mg) prefilled syringes Please note Schedule 3 D and is subject to special prescription requirements and to safe custody requirements. For onsultant Paediatrician use in the community setting as an alternative to rectal diazepam for epilepticus. For use in A&E as an alternative to rectal diazepam for epilepticus for children and adolescents. For use by the palliative care team as an alternative to rectal diazepam for patients dying at home. For supply to Dental linics for use in case of medical emergency Please note this is a different strength to the unlicensed product.

20 Original Date of issue: 26/11/2005 Last eviewed:10/10/2012 Version:4 Page 20 of 25 Although records in registers do not need to be kept we have decided at ANHSFT that we will keep a D register for these both in pharmacy and on the wards where it is stocked (A&E and ward 17) Epi Midazolam Buccal liquid (10mg/1ml) 4ml bottle with measuring syringes provided. It should be prescribed by the brand name with the dose in mls and mgs. Dose by buccal adminisatration: Adult over 18 [unlicensed], 10mg repeated once after 10minutes if necessary hild up to 6 months [unlicensed], 300micrograms/kg (max 2.5mg), 6months -1year 2.5mg, 1-5 years 5mg, 5 10 years 7.5mg, years 10mg; these doses may be repeated once after 10minutes if necessary This is an unlicensed preparation and requires the unlicensed medicines paperwork filling in by the consultant. It should only be used if the doses available in the licensed preparation are not appropriate. Please note this is a different strength to the licensed product. It should be prescribed by the brand name with the dose in mls and mgs. 4.9 Drugs used in parkinsonism and related disorders Dopaminergic drugs used in parkinsonism Dopamine receptor agonists o-beneldopa apsules (12.5/50, 25/100) o-beneldopa M apsules (25/100) o-beneldopa Dispersible Tablets (12.5/50, 25/100) o-careldopa Tablets (12.5/50, 25/100, 10/100, 25/250) o-careldopa M Tablets (25/100, 50/200) Formulary Apomorphine Pens (30mg/3ml, 50mg/10ml) onsultant Neurologist and Department of Elderly Medicine

21 Original Date of issue: 26/11/2005 Last eviewed:10/10/2012 Version:4 Page 21 of 25 Pramipexole tablets 88micrograms base = 125micrograms salt 180micrograms base = 250micrograms salt 350micrograms base = 500micrograms salt 700micrograms base = 1mg salt opinirole Tablets (250mcg, 1mg, 2mg, 3mg, 5mg) opinirole S tablets (2mg, 4mg, 8mg) opinirole Starter Pack otigotine transdermal patches (2mg, 4mg, 6mg, 8mg/24h) Monoamine-oxidase-B inhibitors Selegiline Tablets (5mg) Selegiline Liquid (10mg/5ml) Physician use only onsultant Neurologist and Department of Elderly Medicine Physician use only. eserved for patients WITH Parkinson s disease who have not responsed to or who are intolerant of ropinirole. Moderate to severe restless leg syndrome onsultant Neurologist and Department of Elderly Medicine Physician use only estricted to use in patients with advanced Parkinson s disease with swallowing difficulties Formulary asagiline tablets 1mg onsultant Neurologist and Department of Elderly Medicine Physician use only. For patients intolerant of selegiline or who are likely to develop psychotic side effects or sleep disturbances as a result of treatment atechol-o-methyltransferase inhibitors Formulary S Entacapone tablets 200mg For specialist initiation only Glutamate inhibitors Formulary Amantadine capsules 100mg For use by onsultant Neurologist and Department of Elderly Medicine Physicians

22 Original Date of issue: 26/11/2005 Last eviewed:10/10/2012 Version:4 Page 22 of 25 ombination s in-line with NIE G35 Formulary Stalevo tablets (o-careldopa + entacapone) (50mg/12.5mg/200mg, 75mg/18.75mg/200mg, 100mg/25mg/200mg, 150mg/37.5mg/200mg, 200mg/50mg/200mg) estricted to patients with Parkinson s disease requiring triple therapy with levodopa, carbidopa and entacapone Antimuscarinic drugs used in parkinsonism Orphenadrine Elixir (25mg/5ml) Orphenadrine Tablets (50mg) Procyclidine Tablets (5mg) Procyclidine Injection (10mg/2ml) Procyclidine SF Syrup (5mg/5ml) Trihexyphenidyl Syrup (5mg/5ml) Trihexyphenidyl Tablets (2mg, 5mg) Drugs used in essential tremor, chorea, tics, and related disorders Tetrabenazine Tablets (25mg) Formulary Botulinum A Toxin 100unit vial (Botox Injection) estricted to onsultant Urologist/Neurologist/Orthopaedic/Maxillofacial use only. All other requests should be authorised by a senior clinical pharmacist. Botox units are not equivalent to Dysport units.

23 Original Date of issue: 26/11/2005 Last eviewed:10/10/2012 Version:4 Page 23 of 25 Botulinum A Toxin 100units vial (Xeomin Injection) Botulinum B Toxin 2,500units in 0.5ml (Neurobloc Injection) onsultant in ehab Medicine has agreed to use this brand for her patients if clinically appropriate. Xeomin units are considered to be equivalent to Botox units For use by onsultant Neurologist in patients who have been transeferred from Leeds back to ANHSFT iluzole tablets (50mg) onsultant Neurologist use only. For patients with AML form of motor neurone disease

24 Original Date of issue: 26/11/2005 Last eviewed:10/10/2012 Version:4 Page 24 of Drugs used in substance dependence Buprenorphine Tablets (Subutex) (2mg, 8mg) Nicotine patches Nicorette inhalator 10mg refill Nicorette inhalator Starter Pack Nicotinell 1mg lozenges Niquitin Q 7mg patches (24 hour) Niquitin Q 14mg patches (24 hour) Niquitin Q 21mg patches (24 hour) Niquitin Minis lozenges 1.5mg, 4mg Formulary Acamprosate E/ Tablets onsultant Psychiatrist use only (333mg) Methadone Mixture (1mg/1ml) estricted for treatment of opioid addiction Methadone SF Mixture (1mg/1ml) Methadone Tablets (5mg) Methadone Injection (10mg/1ml) Nicorette 2mg gum Initiated by smoking cessation nurse. Niquitin Q Lozenges (2mg, Initiated by smoking cessation nurse. 4mg) Varenicline Tablets (0.5mg, 1mg) Initiated by smoking cessation nurse or for existing patients. Varenicline Tablets Initiation Pack For use in-line with NIE TA123 (July 2007) Initiated by smoking cessation nurse. For use in-line with NIE TA123 (July 2007)

25 Original Date of issue: 26/11/2005 Last eviewed:10/10/2012 Version:4 Page 25 of 25 Formulary 4.11 Drugs for dementia Donepezil Tablets (5mg, 10mg) Donepezil orodispersible Tablets (10mg) Galantamine Solution (4mg/ml) Galantamine Tablets (8mg) For treatment of moderate Alzheimer s disease. onsultant Psychiatrist and Department of Elderly Medicine Physician use only. For use in-line with NIE TA217 (March 2011). estricted for BDT, 8mg must not be halved, 4mg doses use solution. For use in-line with NIE TA217 (March 2011). Memantine Tablets 10mg For use in-line with NIE TA217 (March 2011). ivastigmine apsules 1.5mg, 3mg, 4.5mg, 6mg ivastigmine oral solution (2mg/ml) ivastigmine transdermal patches (4.6mg/24hrs, 9.5mg/24hrs) For the treatment of Parkinson s disease dementia. Treatment initiated at ANHSFT and continued in Primary are under a Shared are Guideline. For other indications - estricted to Bradford District are Trust and patients who come in on it. For use in-line with NIE TA217 (March 2011).

Medicines Formulary BNF Section 4 Central Nervous System

Medicines Formulary BNF Section 4 Central Nervous System Medicines BNF Section 4 4.1 Hypnotics and anxiolytics Chloral Hydrate 500mg/5ml Solution Clomethiazole 192mg Capsules Lormetazepam Tablets Melatonin Capsules Nitrazepam Suspension Nitrazepam Tablets Temazepam

More information

Chapter 4 ~ Central nervous system

Chapter 4 ~ Central nervous system Chapter 4 ~ Central Nervous System: Special Section 1 of 5 Chapter 4 ~ Central nervous system 4.1 Hypnotics and anxiolytics 4.1.1 Hypnotics LOPRAZOLAM Tablet 1mg LORMETAZEPAM Tablet 500microgram PROMETHAZINE

More information

Chapter 4 ~ Central nervous system

Chapter 4 ~ Central nervous system Chapter 4 ~ Central Nervous System: General Section 1 of 6 Chapter 4 ~ Central nervous system 4.1 Hypnotics and anxiolytics 4.1.1 Hypnotics CHLORAL HYDRATE CLOMETHIAZOLE NITRAZEPAM TEMAZEPAM TRICLOFOS

More information

South London and the Maudsley NHS Foundation Trust Medicines Formulary

South London and the Maudsley NHS Foundation Trust Medicines Formulary South London and the Maudsley NHS Foundation Trust Medicines Formulary Medicine Formulations Restrictions Additional Information / Related NICE Technology Appraisal 4.1 Hypnotics and anxiolytics 4.1.1

More information

NI Formulary: Chapter 4 Central Nervous system

NI Formulary: Chapter 4 Central Nervous system Hypnotics Anxiolytics Acute state Non drug treatment Temazepam tablets 10mg, 20mg; oral solution 10mg/5ml or Zolpidem tablets 5mg, 10mg or Zopiclone 3.75mg, 7.5mg Non drug treatment Diazepam tablets 2mg,

More information

Safe transfer of prescribing guidance

Safe transfer of prescribing guidance Safe transfer of prescribing guidance TEWV Prescriber Summary Application required before prescribing Products requiring an application, before prescribing, using the single application form Unlicensed

More information

Chapter 4 Central Nervous System

Chapter 4 Central Nervous System Chapter 4 Central Nervous System 4.1 Hypnotics and anxiolytics. Insomnia Underlying causes should be identified and treated e.g. depression, anxiety, pain, pruritis, and dyspnoea. In-patients who are prescribed

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Neuropathic pain pharmacological management: the pharmacological management of neuropathic pain in adults in non-specialist

More information

Analgesia. This is widely used in palliative care. It has antipyretic and analgesic effects but no anti-

Analgesia. This is widely used in palliative care. It has antipyretic and analgesic effects but no anti- Page 1 of 8 Analgesia The World Health Organisation (WHO, 1990) has devised a model to assist health care professionals in the management of cancer pain. The recommendations include managing pain, by the

More information

Formulary Item Restrictions and/or Advice Site availability

Formulary Item Restrictions and/or Advice Site availability Formulary Item Restrictions and/or Advice Site availability C&W CNWL Typical Antipsychotic drugs Chlorpromazine 25mg Chlorpromazine 50mg Chlorpromazine 100mg Chlorpromazine 25mg/5ml syrup Chlorpromazine

More information

Joint Formulary for Psychotropic Medication.

Joint Formulary for Psychotropic Medication. Joint for Psychotropic Medication. This document has been produced in collaboration with the Lancashire Commissioning Support Unit Page 1 Table of Contents Section Page Number Page 2 Definition of categories

More information

tablet/capsule Paracetamol 500mg

tablet/capsule Paracetamol 500mg Formulary Item Restrictions and/or Advice Non-opioid analgesics + compound analgesic preparations Aspirin 75mg dispersible Aspirin 300mg dispersible Aspirin 300mg Aspirin 75mg EC Paracetamol 500mg / Paracetamol

More information

This document has been produced in collaboration with the Lancashire Commissioning Support Unit

This document has been produced in collaboration with the Lancashire Commissioning Support Unit Joint for Psychotropic Medication. This document has been produced in collaboration with the Lancashire Commissioning Support Unit Date: December 2014. Reviewed August 2016. Next review Date April 2019

More information

For patients and their carers this means smoother symptom control, better support in a crisis, and avoidance of admission if that is their choice.

For patients and their carers this means smoother symptom control, better support in a crisis, and avoidance of admission if that is their choice. Bedfordshire Palliative Care Palliative Care Medicines Guidance This folder has been produced to support professionals providing palliative care in any setting. Its aim is to make best practice in palliative

More information

Introduction to Drug Treatment

Introduction to Drug Treatment Introduction to Drug Treatment LPT Gondar Mental Health Group www.le.ac.uk Introduction to Psychiatric Drugs Drugs and Neurotransmitters 5 Classes of Psychotropic medications Mechanism of action Clinical

More information

Mid Essex Locality Guideline for Management of Adult Acute and Chronic Non-Cancer Pain in Primary care

Mid Essex Locality Guideline for Management of Adult Acute and Chronic Non-Cancer Pain in Primary care Guideline for Management of Adult Acute and Chronic Non-Cancer Pain in Primary care If possible patients should be assessed using a simple visual analogue scale VAS to determine the most appropriate stage

More information

Derbyshire Medicines Management, Prescribing and Guidelines DERBYSHIRE PRIMARY CARE FORMULARY

Derbyshire Medicines Management, Prescribing and Guidelines DERBYSHIRE PRIMARY CARE FORMULARY Derbyshire Medicines Management, Prescribing and Guidelines DERBYSHIRE PRIMARY CARE FORMULARY Chapter 4: CENTRAL NERVOUS SYSTEM Updated: March 2017 Drugs and driving From March 2015 a new driving offence

More information

Pregnancy. General Principles of Prescribing in Pregnancy (The Maudsley, 12 th Edition)

Pregnancy. General Principles of Prescribing in Pregnancy (The Maudsley, 12 th Edition) Pregnancy General Principles of Prescribing in Pregnancy (The Maudsley, 12 th Edition) In all women of child bearing potential Always discuss the possibility of pregnancy; half of all pregnancies are unplanned

More information

Berkshire West Area Prescribing Committee Guidance

Berkshire West Area Prescribing Committee Guidance Guideline Name Berkshire West Area Prescribing Committee Guidance Date of Issue: September 2015 Review Date: September 2017 Date taken to APC: 2 nd September 2015 Date Ratified by GP MOC: Guidelines for

More information

FORMULARY AND PRESCRIBING GUIDELINES 2017

FORMULARY AND PRESCRIBING GUIDELINES 2017 FORMULARY AND PRESCRIBING GUIDELINES 2017 1 Document Control Summary Issue Date Amended Section /page Author/ Amended by 1. Sept 06 All Jane Moriba Summary of Change Removed Trust policy and guideline

More information

Guidelines for the Management of Chronic Non-Malignant Pain (CNMP) in Primary Care (not including neuropathic pain (NeP).

Guidelines for the Management of Chronic Non-Malignant Pain (CNMP) in Primary Care (not including neuropathic pain (NeP). Surrey (East Surrey CCG, Guildford & Waverley CCG, North West Surrey CCG, Surrey Downs CCG & Surrey Heath CCG) North East Hampshire & Farnham CCG and Crawley, Horsham & Mid-Sussex CCG Guidelines for the

More information

PRESCRIBING PRACTICE IN DELIRIUM. John Warburton Critical Care Pharmacist

PRESCRIBING PRACTICE IN DELIRIUM. John Warburton Critical Care Pharmacist PRESCRIBING PRACTICE IN DELIRIUM John Warburton Critical Care Pharmacist Learning outcomes Modifiable medication risk factors for delirium An appreciation of contributing factors modifiable with medicines

More information

Conservative Management of Uraemia

Conservative Management of Uraemia Conservative Management of Uraemia Information for Health Professionals Renal Department The York Hospital and Scarborough Hospital Tel: 01904 725370 For more information, please contact: The Renal Specialist

More information

Chapter 4 Central Nervous System Answers. 1. What advice would you provide to someone who has just been initiated on Temazepam for insomnia?

Chapter 4 Central Nervous System Answers. 1. What advice would you provide to someone who has just been initiated on Temazepam for insomnia? Chapter 4 Central Nervous System Answers 1. What advice would you provide to someone who has just been initiated on Temazepam for insomnia? May impair judgement and increase reaction time, and so affect

More information

BACKGROUND Measuring renal function :

BACKGROUND Measuring renal function : A GUIDE TO USE OF COMMON PALLIATIVE CARE DRUGS IN RENAL IMPAIRMENT These guidelines bring together information and recommendations from the Palliative Care formulary (PCF5 ) BACKGROUND Measuring renal

More information

Doncaster & Bassetlaw Cancer Locality. Palliative Care Core Formulary

Doncaster & Bassetlaw Cancer Locality. Palliative Care Core Formulary Doncaster & Bassetlaw Cancer Locality Palliative Core Formulary Approved by Doncaster & Bassetlaw Hospitals NHS Foundation Trust Drugs and Therapeutics Committee. DJ14/2155 Oct 2014 Review date: Oct 2017

More information

PRESCRIBING GUIDELINES FOR SYMPTOM MANAGEMENT IN THE DYING PATIENT

PRESCRIBING GUIDELINES FOR SYMPTOM MANAGEMENT IN THE DYING PATIENT PRESCRIBING GUIDELINES FOR SYMPTOM MANAGEMENT IN THE DYING PATIENT A collaboration between: St. Rocco s Hospice, Bridgewater Community Healthcare NHS Trust, NHS Warrington Clinical Commissioning Group,

More information

ALAMEDA COUNTY BEHAVIORAL HEALTH CARE SERVICES MEDICATION FORMULARY

ALAMEDA COUNTY BEHAVIORAL HEALTH CARE SERVICES MEDICATION FORMULARY ANTIDEPRESSANTS Serotonin Selective Reuptake Inhibitors citalopram 10, 20, 40 mg, 10 mg/5cc $ 0.40 No escitalopram 10, 20 mg $ 2.60 Yes fluoxetine 10, 20 mg, 20 mg/5 ml $ 0.40 Yes fluvoxamine 25, 50, 100

More information

Algorithms for Symptom Management. In End of Life Care

Algorithms for Symptom Management. In End of Life Care Algorithms for Symptom Management In End of Life Care The Use of Drugs Beyond Licence (off label) -The Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK regulates the activity of the

More information

Medicine Related Falls Risk Assessment Tool (MrFRAT) User Guide for Age Related Residential Care Facility Staff in Hawke s Bay

Medicine Related Falls Risk Assessment Tool (MrFRAT) User Guide for Age Related Residential Care Facility Staff in Hawke s Bay Medicine Related Falls Risk Assessment Tool (MrFRAT) User Guide for Age Related Residential Care Facility Staff in Hawke s Bay (Revised edition November 2015) The Medicine Related Falls Risk Assessment

More information

End of life prescribing guidance

End of life prescribing guidance End of life prescribing guidance Introduction This guidance has been prepared to ASSIST IN DECISION MAKING for the prescribing and monitoring of medicines useful in the management of symptoms commonly

More information

21 st June BDS BASHD Therapeutics Pain and Analgesia. BASHD Therapeutics Analgesics and Pain Management. Links to other BASHD content

21 st June BDS BASHD Therapeutics Pain and Analgesia. BASHD Therapeutics Analgesics and Pain Management. Links to other BASHD content Volume of Prescribing by Dentists 2011 ( a reminder) BASHD Therapeutics Analgesics and Pain Management Analgesics account for 1 in 80 dental prescriptions made A lot more analgesics will be suggested for

More information

Medicine Related Falls Risk Assessment Tool (MRFRAT)

Medicine Related Falls Risk Assessment Tool (MRFRAT) Medicine Related Falls Risk Assessment Tool (MRFRAT) The Medicine Related Falls Risk Assessment tool (MRFRAT) in Appendix 1 is designed to help identify patients at risk of falls due to their current medicine

More information

Renal Palliative Care Last Days of Life

Renal Palliative Care Last Days of Life Renal Palliative Care Last Days of Life Introduction This guideline is an aid to clinical decision-making and good practice for patients with stage 4-5 chronic kidney disease (egfr

More information

NSFT Formulary. Double Red Not recommended for routine use/not commissioned. These drugs have not been recommended for routine use at present.

NSFT Formulary. Double Red Not recommended for routine use/not commissioned. These drugs have not been recommended for routine use at present. Traffic Light Status NSFT Formulary Not recommended for routine use/not commissioned. These drugs have not been recommended for routine use at present. Hospital/Specialist only Drugs for which the Trust

More information

SYMPTOM MANAGEMENT GUIDANCE FOR PATIENTS RECEIVING PALLIATIVE CARE AT ROYAL DERBY HOSPITAL

SYMPTOM MANAGEMENT GUIDANCE FOR PATIENTS RECEIVING PALLIATIVE CARE AT ROYAL DERBY HOSPITAL SYMPTOM MANAGEMENT GUIDANCE FOR PATIENTS RECEIVING PALLIATIVE CARE AT ROYAL DERBY HOSPITAL If a patient is believed to be approaching the end of their life, medication should be prescribed in anticipation

More information

Syringe driver in Palliative Care

Syringe driver in Palliative Care Syringe driver in Palliative Care Introduction: Syringe drivers are portable, battery operated devices widely used in palliative care to deliver medication as a continuous subcutaneous infusion over 24

More information

Medication For Migraine Chart: Table 1: Acute Treatment when the attack begins

Medication For Migraine Chart: Table 1: Acute Treatment when the attack begins Medication For Migraine Chart: Table 1: Acute Treatment when the attack begins Page a Analgesics (painkillers) Non-steroidal antiinflammatory drugs (NSAIDs) Prescription required Brand Name Formulation

More information

Supportive Care. End of Life Phase

Supportive Care. End of Life Phase Supportive Care End of Life Phase Guidelines for Health Care Professionals In the care of patients with established renal failure who are in the last days of life References: Chambers E J (2004) End of

More information

Psychotropic Medication Use in Dementia

Psychotropic Medication Use in Dementia Psychotropic Medication Use in Dementia Marie A DeWitt, MD Diplomate of the American Board of Psychiatry and Neurology, Specialization in Psychiatry & Subspecialization in Geriatric Psychiatry Staff Physician,

More information

GUIDELINES ON THE MANAGEMENT OF PAIN DUE TO CANCER IN ADULTS

GUIDELINES ON THE MANAGEMENT OF PAIN DUE TO CANCER IN ADULTS GUIDELINES ON THE MANAGEMENT OF PAIN DUE TO CANCER IN ADULTS Bristol Palliative Care Collaborative Contact Numbers: Hospital Specialist Palliative Care Teams: North Bristol 0117 4146392 UH Bristol 0117

More information

MANAGEMENT OF PATIENTS WITH PARKINSON S DISEASE WHO ARE NIL BY MOUTH OR WITH A COMPROMISED SWALLOW

MANAGEMENT OF PATIENTS WITH PARKINSON S DISEASE WHO ARE NIL BY MOUTH OR WITH A COMPROMISED SWALLOW MANAGEMENT OF PATIENTS WITH PARKINSON S DISEASE WHO ARE NIL BY MOUTH OR WITH A COMPROMISED SWALLOW Author: Gordon W Duncan Status: Approved Authorised by: Clinical Policy Group Version: 1.0 Review date:

More information

AETNA BETTER HEALTH Prior Authorization guideline for Narcotic Analgesic Utilization

AETNA BETTER HEALTH Prior Authorization guideline for Narcotic Analgesic Utilization AETNA BETTER HEALTH Prior Authorization guideline for Narcotic Analgesic Utilization Policy applies to all formulary and non-formulary schedules II V opioid narcotics, including tramadol and codeine, as

More information

Chapter 4 Central Nervous System

Chapter 4 Central Nervous System Chapter 4 page number 1 Chapter 4 Central Nervous System First line drugs Drugs recommended in both primary and secondary care Second line drugs Alternatives (often in specific conditions) in both primary

More information

PAIN MANAGEMENT Person established taking oral morphine or opioid naive.

PAIN MANAGEMENT Person established taking oral morphine or opioid naive. PAIN MANAGEMENT Person established taking oral morphine or opioid naive. Important; it is the responsibility of the prescriber to ensure that guidelines are followed when prescribing opioids. Every member

More information

FORMULARY AND PRESCRIBING GUIDANCE

FORMULARY AND PRESCRIBING GUIDANCE FORMULARY AND PRESCRIBING GUIDANCE GUIDELINE VERSION 18 RATIFYING GROUP Drugs and Therapeutics Group (DTG) DATE PUBLISHED NEXT REVIEW DATE (see specific guidelines) FORMULARY SPONSOR Executive Medical

More information

Original Date of issue: 01/11/2005 Last Reviewed: 01/05/2011 Version:4 Page 1 of 7

Original Date of issue: 01/11/2005 Last Reviewed: 01/05/2011 Version:4 Page 1 of 7 Original Date of issue: 01/11/2005 Last eviewed: 01/05/2011 Version:4 Page 1 of 7 15: Anaesthesia 15.1 General anaesthesia 15.1.1 Intravenous anaesthesia Etomidate Injection (20mg/10ml) Ketamine Injection

More information

PAIN MANAGEMENT Patient established on oral morphine or opioid naive.

PAIN MANAGEMENT Patient established on oral morphine or opioid naive. PAIN MANAGEMENT Patient established on oral morphine or opioid naive. Important; It is the responsibility of the prescriber to ensure that guidelines are followed when prescribing opioids. Every member

More information

What s New 2003? What new treatments? What have you discontinued? More information please!

What s New 2003? What new treatments? What have you discontinued? More information please! What s New 2003? What new treatments? What have you discontinued? More information please! 1 What s New 2003? Submissions = 137 UK = 52 (38%) Doctors = 60% Nurses = 25% Pharmacists = 15% 2 What s New?

More information

Drugs used for the treatment of pain Simple Analgesics Weak Opioids Strong Opioids Oral Strong Opioids Transdermal Strong Opioids Subcutaneous

Drugs used for the treatment of pain Simple Analgesics Weak Opioids Strong Opioids Oral Strong Opioids Transdermal Strong Opioids Subcutaneous Drugs used for the treatment of Simple Analgesics Weak Opioids Strong Opioids Oral Strong Opioids Transdermal Strong Opioids Subcutaneous Adjuvant analgesics Non Steroidal Anti-Inflammatory Drugs (NSAIDs)

More information

Symptom Control in the Community Setting. Dr Andrew Tysoe-Calnon

Symptom Control in the Community Setting. Dr Andrew Tysoe-Calnon Symptom Control in the Community Setting Dr Andrew Tysoe-Calnon Lead Consultant t Common symptoms Pain Agitation Shortness of breath Nausea and vomiting Intestinal obstruction Confusion Pain Occurs in

More information

Care in the Last Days of Life

Care in the Last Days of Life Care in the Last Days of Life Introduction This guideline is an aid to clinical decision making and good practice in person-centred care for patients who are deteriorating and at risk of dying. The patient

More information

Supporting Last Days of Life Symptom Control Medication Guidance: Algorithm. Agitation & Anxiety

Supporting Last Days of Life Symptom Control Medication Guidance: Algorithm. Agitation & Anxiety Agitation & Anxiety (Exclude or treat REVERSIBLE causes*) Patient is anxious / frightened, but lucid Patient is confused, agitated and / or hallucinating MIDAZOLAM 2.5-5mg s/c (Max total 24 hour dose of

More information

Chapter 4 Central Nervous System

Chapter 4 Central Nervous System Chapter 4 page number 1 Chapter 4 Central Nervous System First line drugs Drugs recommended in both primary and secondary care Second line drugs Alternatives (often in specific conditions) in both primary

More information

Guidelines on Choice and Selection of Antidepressants for the Management of Depression

Guidelines on Choice and Selection of Antidepressants for the Management of Depression Guidelines on Choice and Selection of Antidepressants for the Management of Depression 1. Introduction This guidance should be considered as part of a stepped care approach in the management of depressive

More information

Analgesia in patients with impaired renal function Formulary Guidance

Analgesia in patients with impaired renal function Formulary Guidance Analgesia in patients with impaired renal function Formulary Guidance Approved by Trust D&TC: January 2010 Revised March 2017 Contents Paragraph Page 1 Aim 4 2 Introduction 4 3 Assessment of renal function

More information

Formulary and Prescribing Guidelines

Formulary and Prescribing Guidelines Formulary and Prescribing Guidelines SECTION 3: TREATMENT OF BIPOLAR AFFECTIVE DISORDER This section provides information regarding the pharmacological management of Bipolar affective disorder in secondary

More information

Psychopharmacology. Psychopharmacology. Hamish McAllister-Williams Reader in Clinical. Department of Psychiatry, RVI

Psychopharmacology. Psychopharmacology. Hamish McAllister-Williams Reader in Clinical. Department of Psychiatry, RVI Regional Affective Disorders Service Psychopharmacology Northumberland, Tyne and Wear NHS Trust Hamish McAllister-Williams Reader in Clinical Psychopharmacology Department of Psychiatry, RVI Intro NOT

More information

Palliative Care Out-of-hours. A resource pack for West Dorset. Contents:

Palliative Care Out-of-hours. A resource pack for West Dorset. Contents: Palliative Care Out-of-hours. A resource pack for West Dorset Contents: Section 1 Supply of drugs DCH Pharmacy hours and arrangements How to contact a community pharmacist out of hours Palliative care

More information

Clinical Guideline for the management of inpatients with Parkinson s disease

Clinical Guideline for the management of inpatients with Parkinson s disease Clinical Guideline for the management of inpatients with Parkinson s disease Introduction: Parkinson s disease (PD) is the second most common neurodegenerative disorder, characterised by bradykinesia,

More information

Palliative care for heart failure patients. Susan Addie

Palliative care for heart failure patients. Susan Addie Palliative care for heart failure patients Susan Addie Treatments The most common limiting and distressing complaint is of fatigue and breathlessness. Optimal treatment strategies relieve symptoms, improves

More information

Chapter 4 Central Nervous System

Chapter 4 Central Nervous System Chapter 4 page number 1 Chapter 4 Central Nervous System First line drugs Drugs recommended in both primary and secondary care Second line drugs Alternatives (often in specific conditions) in both primary

More information

PHARMACY SERVICE ARRANGEMENTS FOR THE SUPPLY OF PALLIATIVE CARE SYRINGES AND MEDICINES FOR COMMUNITY PATIENTS

PHARMACY SERVICE ARRANGEMENTS FOR THE SUPPLY OF PALLIATIVE CARE SYRINGES AND MEDICINES FOR COMMUNITY PATIENTS PHARMACY SERVICE ARRANGEMENTS FOR THE SUPPLY OF PALLIATIVE CARE SYRINGES AND MEDICINES FOR COMMUNITY PATIENTS The benefits of prefilled syringes for palliative care from the hospital pharmacy service In

More information

Pain. Christine Illingworth. Community Nurse St Luke s Hospice 17/5/17

Pain. Christine Illingworth. Community Nurse St Luke s Hospice 17/5/17 Pain Christine Illingworth Community Nurse St Luke s Hospice 17/5/17 What is pain? Pain is an unpleasant sensory and emotional experience associated with actual or potential tissue damage Pain is whatever

More information

Perinatal Mental Health: Prescribing Guidance for Trust Prescribers and GPs

Perinatal Mental Health: Prescribing Guidance for Trust Prescribers and GPs Perinatal Mental Health: Prescribing Guidance for Trust Prescribers and GPs (Version 3 January 2015) Principal Author: Dr Jenny Cooke Consultant Psychiatrist, Brighton & Hove Perinatal Mental Health Service

More information

Regional Renal Training

Regional Renal Training Regional Renal Training Palliative and End of Life Care Dr Clare Kendall North Bristol NHS Trust Advanced Kidney Disease Dialysis/Transplant Conservative Management Deteriorating despite dialysis/failing

More information

SYRINGE DRIVER MEDICATIONS

SYRINGE DRIVER MEDICATIONS SYRINGE DRIVER MEDICATIONS Christine Hull & Anita Webb Staff Nurses, Hospice in the Home 2015 Analgesics:- Groups of Medication used in Syringe Drivers Morphine sulphate Diamorphine Oxycodone Alfentanil

More information

ABILIFY INJ. Products Affected Step 2: ABILIFY MAINTENA PREFILLED SYRINGE 300 MG INTRAMUSCULAR ABILIFY MAINTENA PREFILLED SYRINGE 400 MG INTRAMUSCULAR

ABILIFY INJ. Products Affected Step 2: ABILIFY MAINTENA PREFILLED SYRINGE 300 MG INTRAMUSCULAR ABILIFY MAINTENA PREFILLED SYRINGE 400 MG INTRAMUSCULAR ABILIFY INJ ABILIFY MAINTENA PREFILLED SYRINGE 300 MG ABILIFY MAINTENA PREFILLED SYRINGE 400 MG ABILIFY MAINTENA SUSPENSION RECONSTITUTED ER 300 MG Claim will pay automatically for ABILIFY MAINTENA if

More information

Your A-Z of Pain Relief A guide to pain relief medicines. We care, we discover, we teach

Your A-Z of Pain Relief A guide to pain relief medicines. We care, we discover, we teach Your A-Z of Pain Relief A guide to pain relief medicines We care, we discover, we teach Which pain medicines are you taking? Abstral (see Fentanyl Instant Tablets) Amitriptyline 5 Brufen (see Ibuprofen)

More information

APPENDIX T - Unit costs of anti-epileptic drugs for 2012 guideline

APPENDIX T - Unit costs of anti-epileptic drugs for 2012 guideline Drug name APPENDIX T - Unit costs of anti-epileptic drugs for 2012 guideline Unit costs and weighted average unit costs for drug used in the treatment of focal and generalised epilepsies Prescription Cost

More information

Clinical Guideline / Formulary Document Pharmacy Department Medicines Management Services

Clinical Guideline / Formulary Document Pharmacy Department Medicines Management Services Clinical Guideline / Formulary Document Pharmacy Department Medicines Management Services DEPRESSION Pharmacological Treatment of Depression NICE guidelines suggest the following stepped care model also

More information

Dementia Medications Acetylcholinesterase Inhibitors (AChEIs) and Glutamate (NMDA) Receptor Antagonist

Dementia Medications Acetylcholinesterase Inhibitors (AChEIs) and Glutamate (NMDA) Receptor Antagonist Dementia Medications Acetylcholinesterase Inhibitors (AChEIs) and Glutamate (NMDA) Receptor Antagonist Medication Dosage Indication for Use Aricept (donepezil) Exelon (rivastigmine) 5mg 23mg* ODT 5mg Solution

More information

Guidelines on Choice and Selection of Antidepressants for the Management of Depression

Guidelines on Choice and Selection of Antidepressants for the Management of Depression Working in partnership: Hertfordshire Partnership University NHS Foundation Trust East and North Hertfordshire Clinical Commissioning Group Herts Valleys Clinical Commissioning Group Guidelines on Choice

More information

West London Mental Health NHS Trust Formulary

West London Mental Health NHS Trust Formulary West London Mental Health NHS Trust Formulary VERSION 3.0 (18.02.15) The Formulary is a list of medicines used for mental health indications for patients cared for in all settings of West London Mental

More information

SYMPTOM CONTROL IN THE LAST DAYS OF LIFE. Bradford, Airedale, Wharfedale & Craven

SYMPTOM CONTROL IN THE LAST DAYS OF LIFE. Bradford, Airedale, Wharfedale & Craven Bradford, Airedale, Wharfedale & Craven Managed Clinical Network SYMPTOM CONTROL IN THE LAST DAYS OF LIFE Guidelines for Healthcare Professionals Bradford, Airedale, Wharfedale & Craven Signs and symptoms

More information

PAIN AND SYMPTOM MANAGEMENT GUIDANCE IN THE LAST DAYS OF LIFE

PAIN AND SYMPTOM MANAGEMENT GUIDANCE IN THE LAST DAYS OF LIFE PAIN AND SYMPTOM MANAGEMENT GUIDANCE IN THE LAST DAYS OF LIFE Reference: DCM029 Version: 1.1 This version issued: 07/06/18 Result of last review: Minor changes Date approved by owner (if applicable): N/A

More information

GUIDELINES AND AUDIT IMPLEMENTATION NETWORK

GUIDELINES AND AUDIT IMPLEMENTATION NETWORK GUIDELINES AND AUDIT IMPLEMENTATION NETWORK General Palliative Care Guidelines The Management of Pain at the End Of Life November 2010 Aim To provide a user friendly, evidence based guide for the management

More information

Palliative Prescribing - Pain

Palliative Prescribing - Pain Palliative Prescribing - Pain LAURA BARNFIELD 21/2/17 Aims To understand the classes of painkillers available in palliative care To gain confidence in counselling regarding opiates To gain confidence prescribing

More information

Ketamine and Methadone Supra- Regional Audit Presentation

Ketamine and Methadone Supra- Regional Audit Presentation Ketamine and Methadone Supra- Regional Audit Presentation Audit Group: Alison Coackley, Anthony Thompson, Graham Whyte, Helen Bonwick, Ruth Clark, Agnes Noble, Aileen Scott, Andrew Dickman, Sarah Fradsham

More information

SECTION 9 : MANAGEMENT OF MOVEMENT DISORDERS AND EXTRAPYRAMIDAL SIDE EFFECTS

SECTION 9 : MANAGEMENT OF MOVEMENT DISORDERS AND EXTRAPYRAMIDAL SIDE EFFECTS SECTION 9 : MANAGEMENT OF MOVEMENT DISORDERS AND EXTRAPYRAMIDAL SIDE EFFECTS Formulary and Prescribing Guidelines 9.1 Introduction Movement disorders and extrapyramidal side effects can manifest in the

More information

Mentoring Session: Participant Cases

Mentoring Session: Participant Cases Handout for the Neuroscience Education Institute (NEI) online activity: Mentoring Session: Participant Cases The Case: 55-year-old patient with depression and anxiety The Question: What to do when antidepressants

More information

MMG035 Symptom Management Guidelines for a Person thought to be in the Last Few Days and Hours of Life

MMG035 Symptom Management Guidelines for a Person thought to be in the Last Few Days and Hours of Life MMG035 Symptom Management Guidelines for a Person thought to be in the Last Few Days and Hours of Life The following pages are guidelines for the management of common symptoms for a person thought to be

More information

ACUTE MANAGEMENT OF PARKINSON S PATIENTS WHO ARE NIL BY MOUTH (NBM) OR WHO HAVE A COMPROMISED SWALLOW NHS LANARKSHIRE PARKINSON S TEAM

ACUTE MANAGEMENT OF PARKINSON S PATIENTS WHO ARE NIL BY MOUTH (NBM) OR WHO HAVE A COMPROMISED SWALLOW NHS LANARKSHIRE PARKINSON S TEAM ACUTE MANAGEMENT OF PARKINSON S PATIENTS WHO ARE NIL BY MOUTH (NBM) OR WHO HAVE A COMPROMISED SWALLOW NHS LANARKSHIRE PARKINSON S TEAM 1 CONTENTS: TOPIC PAGE Introduction 3 What should you do when a PD

More information

West London Mental Health NHS Trust Formulary

West London Mental Health NHS Trust Formulary West London Mental Health NHS Trust Formulary VERSION 7.0 (09.11.16) The Formulary is a list of medicines used for mental health indications for patients cared for in all settings of West London Mental

More information

In our patients the cause of seizures can be broadly divided into structural and systemic causes.

In our patients the cause of seizures can be broadly divided into structural and systemic causes. Guidelines for the management of Seizures Amalgamation and update of previous policies 7 (Seizure guidelines, ND, 2015) and 9 (Status epilepticus, KJ, 2011) Seizures can occur in up to 15% of the Palliative

More information

Medications for Anxiety & Behavior in Williams Syndrome. Disclosure of Potential Conflicts. None 9/22/2016. Evaluation

Medications for Anxiety & Behavior in Williams Syndrome. Disclosure of Potential Conflicts. None 9/22/2016. Evaluation Medications for Anxiety & Behavior in Williams Syndrome Christopher J. McDougle, M.D. Director, Lurie Center for Autism Professor of Psychiatry and Pediatrics Massachusetts General Hospital and MassGeneral

More information

Therapeutic options for adult patients unable to take solid oral dosage forms (Adapted from UKMi Q&A for use in Northern Ireland) Sep 2015

Therapeutic options for adult patients unable to take solid oral dosage forms (Adapted from UKMi Q&A for use in Northern Ireland) Sep 2015 Therapeutic options for adult patients unable to take solid oral dosage forms (Adapted from UKMi Q&A 294.3 for use in Northern Ireland) Sep 2015 BNF 1.3.5 Proton pump inhibitors Lansoprazole orodispersible

More information

West Midlands Palliative Care Physicians. Palliative care. Guidelines for the use of drugs in symptom control

West Midlands Palliative Care Physicians. Palliative care. Guidelines for the use of drugs in symptom control West Midlands Palliative Care Physicians Palliative care Guidelines for the use of drugs in symptom control Revised Jan 2012 1 5th Edition, 2012 Guidelines for the use of drugs in symptom control These

More information

End Stage Liver Disease Regional Audit Casenote Survey

End Stage Liver Disease Regional Audit Casenote Survey 1. This questionnaire is an audit of clinical documentation of patients who have died of end stage liver disease. If you have any questions about how this form should be completed please contact Dr Grace

More information

A SLP s Guide to Medication Therapy and Management. Sarah Luby, PharmD, BCPS KSHA 2017

A SLP s Guide to Medication Therapy and Management. Sarah Luby, PharmD, BCPS KSHA 2017 A SLP s Guide to Medication Therapy and Management Sarah Luby, PharmD, BCPS KSHA 2017 Objectives Identify the appropriate route of administration for medications and proper formulations for use Understand

More information

ANTICIPATORY PRESCRIBING FOR PATIENTS AT END OF LIFE WITH RENAL IMPAIRMENT

ANTICIPATORY PRESCRIBING FOR PATIENTS AT END OF LIFE WITH RENAL IMPAIRMENT ANTICIPATORY PRESCRIBING FOR PATIENTS AT END OF LIFE WITH RENAL Doses of opiates must be proptional to current analgesic medication Please refer ALL patients on Methadone Ketamine to SPCT f advice. Patients

More information

Acute management of in-patient Parkinson s Disease patients

Acute management of in-patient Parkinson s Disease patients Acute management of in-patient Parkinson s Disease patients Contents Pages Introduction and Admission advice 2 Nil by Mouth Guidance 3 5 Complex therapy advice (Apomorphine, DBS, Duodopa) 6 Surgical peri-operative

More information

GUIDELINES FOR CONVERSION FROM A STRONG OPIOID TO METHADONE

GUIDELINES FOR CONVERSION FROM A STRONG OPIOID TO METHADONE GUIDELINES FOR CONVERSION FROM A STRONG OPIOID TO METHADONE GENERAL PRINCIPLES Methadone may be used as a strong opioid alternative when severe cancer-related pain responds poorly to other opioids, or

More information

Enhanced Community Palliative Support Services. Lynne Ghasemi St Luke s Hospice

Enhanced Community Palliative Support Services. Lynne Ghasemi St Luke s Hospice Enhanced Community Palliative Support Services Lynne Ghasemi St Luke s Hospice Learning Outcomes Define the different types of pain Describe the process of pain assessment Discuss pharmacological management

More information

Treating sleep disorders

Treating sleep disorders Treating sleep disorders Sue Wilson Centre for Neuropsychopharmacology Imperial College London sue.wilson@imperial.ac.uk Suggested algorithm for treatment of insomnia Diagnosis of insomnia Associated with

More information

HMFP Comprehensive Headache Center Department of Anesthesia, Critical Care and Pain Medicine Beth Israel Deaconess Medical Center Instructor in

HMFP Comprehensive Headache Center Department of Anesthesia, Critical Care and Pain Medicine Beth Israel Deaconess Medical Center Instructor in HMFP Comprehensive Headache Center Department of Anesthesia, Critical Care and Pain Medicine Beth Israel Deaconess Medical Center Instructor in Anesthesia and Neurology Harvard Medical School Limited time

More information

BJF Acute Pain Team Formulary Group

BJF Acute Pain Team Formulary Group Title Analgesia Guidelines for Acute Pain Management (Adults) in BGH Document Type Issue no Clinical guideline Clinical Governance Support Team Use Issue date April 2013 Review date April 2015 Distribution

More information

Palliative Patient in Emergency Department

Palliative Patient in Emergency Department Palliative Patient in Emergency Department Dr Thiru Thirukkumaran Palliative Care Services NW THO Northwest Regional Hospital, Burnie Northwest Tasmania Outline the Session Introduction What is palliative

More information

Anticipatory Medications for End of Life Patients. Doses must be proportional to the current analgesic medication YES NO YES NO

Anticipatory Medications for End of Life Patients. Doses must be proportional to the current analgesic medication YES NO YES NO Anticipatory Medications for End of Life Patients oses must be proportional to the current analgesic medication Please refer ALL patients on Methadone or Ketamine to palliative care team for advice. Patients

More information